Investor Alert

July 30, 2021, 10:58 a.m. EDT

3 Biotech Penny Stocks To Watch On Robinhood IPO Day

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GT Biopharma Inc. (GTBP)
  • X
    PAVmed Inc. (PAVM)

or Cancel Already have a watchlist? Log In

2. PAVmed Inc. /zigman2/quotes/203185294/composite PAVM -5.15%

Like GTBP, shares of PAVM stock have gone from penny stock levels to trading well above $5 a share. This week, the biotech company's stock price reached a fresh 52-week high of $7.50 following a series of key updates. The company's Lucid Diagnostics subsidiary launched a strategic partnership with UpScriptHealth. The detail will see the two companies collaborating to support Lucid's EsoGuard Telemedicine Program. UpScript will provide a branded web platform for telemedicine services. Patients with chronic heartburn can request a video evaluation by a doctor and have an opportunity for a referral to Lucid's EsoGuard Esophageal DNA Test.

What's more, biotech industry vet and former CEO of Exact Sciences ( NASDAQ:EXAS ) joined Lucid's Board as Vice Chairman. Stanley Lapidus was already a strategic advisor to Lucid and now comes on to serve a larger role. "I am joining the Lucid team because they are on that very same quest--to prevent deaths from esophageal cancer as we have done for cervical and colon cancer," said Mr. Lapidus.

The progress from Lucid is one aspect that traders are watching with PAVmed. However, an earlier development this summer may have also acted as a catalyst for the record-setting move in 2021. Once again, this involves Lucid's EsoGuard test. It received a European CE mark certification. This now allows the test to be marketed in numerous European countries.

[Read More] Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth

While PAVmed isn't developing a cancer treatment, the EsoGuard platform is the first step to potential prevention. According to the company, it is the first and only commercially available diagnostic test capable of widespread screening to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients.

3. Intec Pharma Inc.

Finally, Intec is likely one of the biotech penny stocks that are familiar to readers. Had it not been for a recent reverse split, it may have still been trading under $5. However, thanks to a recent deal that will see it merge with another company, Decoy Biosystems, Intec has recently announced a $30 million private placement, and 1 for 4 reverse split ahead of this deal.

While it has been a big part of the discussion on marijuana stocks, Intec also plays a larger role in biotech. One of the core points of interest for the company is its Accordion Pill delivery system. It hopes to enhance the efficacy and safety of existing drugs by utilizing this technology. One of its early state developments for the system is with its "AP-cannabinoids" platform. The goal is the leverage the Accordion Pill to deliver each or a combination of primary cannabinoids within Cannabis sativa, cannabidiol, and tetrahydrocannabinol.

The company recently gained attention after traders circulated a European Patent specification for "Delivery Device For Oral Intake Of An Agent." In particular, the patent stated, "This invention relates generally to apparatuses for forming delivery systems for the controlled release of active agents and more preferably for forming delivery system with gastroretentivity."

Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from Decoy surfaced. It showed that this was for Decoy's "Compositions and methods for treatment of cancer using bacteria' and that the patent was granted. With the latest proposed merger seemingly coming to fruition, this additional piece could give the company more exposure to the mounting cancer trend in the market recently. Shares have catapulted to highs of $17.80 during the week.

Biotech Stocks To Watch Right Now

The long and short of it is that interest continues growing around oncology stocks. With big news from industry leaders like Merck, Bristol Myers, and Novartis, it makes sense that oncology treatment stocks have become a focus. Heading into the second half of the year, it will be interesting to see how upcoming data readouts, mergers, and the like play into some of the companies mentioned above. Are cancer stocks on your watch list right now?

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from June 2, 2021, to July 1, 2021. This compensation is payment 4 of 12 as part of the Agreement. Midam has been paid an additional $200,000 for a period from July 2, 2021, to August 2, 2021. This compensation is payment 5 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click here for full disclaimer .


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

US : U.S.: Nasdaq
$ 1.00
-0.05 -5.15%
Volume: 8.68M
June 24, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$92.37 million
Rev. per Employee

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.